News

Biopharma news, November 16, 2026

4 stories

In this digest: Approval 4

Top stories

  1. ApprovalRoche

    Gazyva Wins Kidney Disease Approval

    The FDA approved Roche's Gazyva for adults with primary membranous nephropathy at risk of progression, making it the first FDA-approved treatment for the disease. In the phase 3 MAJESTY trial, complete remission of proteinuria at two years occurred in 36.1% of patients receiving Gazyva versus 5.7% receiving tacrolimus. Roche reported no new safety signals and said regulators are also considering Gazyva for systemic lupus erythematosus.

    Source types: Press release · News article

  2. Approval

    FDA Approves Perioperative Imfinzi Regimen

    The FDA approved neoadjuvant Imfinzi plus enfortumab vedotin-ejfv followed by adjuvant Imfinzi for adults with muscle-invasive bladder cancer who are ineligible for or refuse cisplatin-based chemotherapy.

    Read more about FDA Approves Perioperative Imfinzi Regimen

    In the phase III VOLGA trial, the regimen reduced the risk of an event by 49% and the risk of death by 42% versus cystectomy with or without approved adjuvant treatment. Grade 3 or 4 adverse events occurred in 64% of patients receiving the regimen versus 44% in the comparator arm; applications are also under review in the EU, Japan and other countries.

    Source types: Press release

  3. Approval

    FDA Approves Imfinzi ADC Regimen

    The FDA approved neoadjuvant Imfinzi plus enfortumab vedotin followed by adjuvant Imfinzi after radical cystectomy for eligible adults with muscle-invasive bladder cancer.

    Read more about FDA Approves Imfinzi ADC Regimen

    The regimen is intended for patients who are ineligible for or decline cisplatin-based chemotherapy, and the approval came six weeks ahead of the FDA's target review date. The approval was based on the phase 3 VOLGA trial, which enrolled 695 patients; its results were presented at ESMO 2026 and published in the New England Journal of Medicine.

    Source types: News article

News in brief

  1. Approval

    China Approves Hengrui ANGPTL3 Antibody

    Read more about China Approves Hengrui ANGPTL3 Antibody

    China approved Hengrui's ANGPTL3 antibody 艾轻达 for use alongside a low-fat diet and other lipid-lowering drugs in adults and adolescents aged 12 or older with homozygous familial hypercholesterolemia. In the phase 3 SHR-1918-301 trial, the treatment reduced LDL cholesterol by 64.2% relative to placebo at week 12; 88.9% of treated patients achieved at least a 50% reduction from baseline at week 24. The drug is administered as a 600 mg subcutaneous injection every four weeks. Additional indications remain in clinical development.

    Source types: Press release

All digests

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call